A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

BOSTON - There is concern over the newest weight loss drugs sparking eating disorders in teens. Newer GLP-1 weight loss drugs ...

The effectiveness can vary based on the individual response and adherence to treatment. Research indicates that GLP-1 ...

A study from tirzepatide's manufacturer found that the GLP-1 drug could significantly improve heart failure symptoms.

Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...

An emerging market for compounded weight loss injections that mimic brand-name drugs such as Ozempic, Wegovy, Mounjaro and ...

Novo Nordisk’s Wegovy has shown promising benefits in treating a common, chronic skin condition hidradenitis suppurative (HS) ...

Editorial writers delve into these public health issues.

Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial ...

The surging popularity of weight-loss drugs, expected to be a $150 billion market by early 2030s, has whetted investor appetite in companies looking to tap into the boom. BioAge priced its offering of ...

Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel ...

The Senate Committee on Health, Education, Labor and Pensions held a hearing on Tuesday, to discuss Novo Nordisk lowering ...